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Abstract
Background: Standard random-effects meta-analysis methods perform poorly when applied to few studies only.
Such settings however are commonly encountered in practice. It is unclear, whether or to what extent
small-sample-size behaviour can be improved by more sophisticated modeling.
Methods: We consider likelihood-based methods, the DerSimonian-Laird approach, Empirical Bayes, several
adjustment methods and a fully Bayesian approach. Confidence intervals are based on a normal approximation, or on
adjustments based on the Student-t-distribution. In addition, a linear mixed model and two generalized linear mixed
models (GLMMs) assuming binomial or Poisson distributed numbers of events per study arm are considered for
pairwise binary meta-analyses. We extract an empirical data set of 40 meta-analyses from recent reviews published by
the German Institute for Quality and Efficiency in Health Care (IQWiG). Methods are then compared empirically as well
as in a simulation study, based on few studies, imbalanced study sizes, and considering odds-ratio (OR) and risk ratio
(RR) effect sizes. Coverage probabilities and interval widths for the combined effect estimate are evaluated to
compare the different approaches.
Results: Empirically, a majority of the identified meta-analyses include only 2 studies. Variation of methods or effect
measures affects the estimation results. In the simulation study, coverage probability is, in the presence of
heterogeneity and few studies, mostly below the nominal level for all frequentist methods based on normal
approximation, in particular when sizes in meta-analyses are not balanced, but improve when confidence intervals are
adjusted. Bayesian methods result in better coverage than the frequentist methods with normal approximation in all
scenarios, except for some cases of very large heterogeneity where the coverage is slightly lower. Credible intervals
are empirically and in the simulation study wider than unadjusted confidence intervals, but considerably narrower
than adjusted ones, with some exceptions when considering RRs and small numbers of patients per trial-arm.
Confidence intervals based on the GLMMs are, in general, slightly narrower than those from other frequentist
methods. Some methods turned out impractical due to frequent numerical problems.
Conclusions: In the presence of between-study heterogeneity, especially with unbalanced study sizes, caution is
needed in applying meta-analytical methods to few studies, as either coverage probabilities might be compromised,
or intervals are inconclusively wide. Bayesian estimation with a sensibly chosen prior for between-trial heterogeneity
may offer a promising compromise.
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Background
Meta-analyses of few studies are common in prac-
tice. For instance, a review of the Cochrane Library
revealed that half of the meta-analyses reported in the
Cochrane Library are conducted with two or three stud-
ies [1]. However, standard random-effects meta-analysis
methods perform poorly when applied to few studies
only [2, 3]. It is unclear, whether or to what extent
small-sample-size behaviour can be improved by more
sophisticated modeling. Bayesian random-effects meta-
analyses with weakly informative priors for the between-
study heterogeneity have been proposed for this set-
ting [4] and their performance has been found to be
satisfactory in numerical applications and simulations
[3, 5]. Other alternative approaches including likeli-
hood based methods have been mentioned as potential
remedies [6].
In meta-analyses commonly a two-stage approach is
applied. In the first step, data from the individual stud-
ies are analyzed resulting in effect estimates with standard
errors. These are then combined in a second step. As indi-
vidual patient data (IPD) are not generally available and
effects with standard errors can typically extracted from
publications, this two-stage approach makes a lot of sense
from a practical point of view. With binary data, how-
ever, the individual patient data are summarized by 2×2
frequency tables and are usually readily available from
publications [7]. Therefore, preference might be given to
one-stage approaches in this setting over the commonly
applied two-stage approach. However, numerical differ-
ences between the one-stage and two-stage approaches
have been found to be small in a simple Gaussian model
[8]. If differences are observed, these arise mostly for dif-
fering models [9, 10] or relate not to the main effects but
interactions [11]. So, while a simpler two-stage model is
often sufficient (especially in case of many studies and
non-rare events), a one-stage model may on the other
hand be expected to be more flexible and more exact [12].
A Bayesian approach may be more suitable especially in
cases of few studies [3–5]. For a more detailed discus-
sion of common models for binary data, see also Jackson
et al. [13].
Although some model and method comparison stud-
ies appeared recently [13, 14], a systematic evaluation and
comparison of the various methods is lacking in the con-
text of few studies. Here we intend to close this gap by an
empirical study and comprehensive simulations.
This manuscript is structured as follows. In the follow-
ing section we summarize the meta-analysis approaches
compared, the extraction of the empirical data set and
the setup of the simulation study. Then the results of
the empirical study as well as of the simulation study
are presented. We close with a brief discussion and some
conclusions.
Methods
Modeling approaches
In the following, we will consider meta-analyses based
on binary endpoints, where each study’s outcome may
be summarized in a 2×2 table giving the the numbers of
participants with andwithout an event in both study arms.
Normal-normal hierarchical model (NNHM)
Model specification
Traditionally, meta-analytical methods often follow a
contrast-based summary measure approach which is
based on the log-transformed empirical estimates of the
outcomemeasure and their standard errors, and assuming
an approximate normal likelihood [15].
In a common situation in random-effects meta-analysis,
k independent studies are available in which the treatment
effect θi is the parameter of interest (i = 1, 2, . . . , k). From
each study, an effect estimate θˆi with its estimated variance
(squared standard error) σ 2i is provided for this treatment
effect. It is then assumed that θˆi follows a normal dis-
tribution centered around the unknown true treatment
effect θi, with the variance σ 2i accounting for the mea-
surement uncertainty, or within-study variation. Although
σ 2i usually only is an estimate, it is commonly treated as
known. The θi may vary across study populations around
a global mean μ due to the between-study heterogene-
ity τ . After integrating out the parameters θi, the marginal
model can be expressed as
θˆi ∼ N
(
μ, σ 2i + τ 2
)
. (1)
This model is commonly applied to both log-
transformed risk ratio (RR) or odds ratio (OR) measures
of treatment effect for binary data θˆi [16, 17]; it is denoted
as “model 1” in the investigation by Jackson et al. [13].
Inference
We will consider frequentist and Bayesian approaches to
inference within the generic NNHM. In the frequentist
approaches, an estimate of the between-study hetero-
geneity τ is usually required first. Different estimators
are available; in the following we consider the commonly
used DerSimonian-Laird (DL) [18], maximum likelihood
(ML), restricted maximum likelihood (REML) [19, 20]
and empirical Bayes (EB) estimators, the latter also being
known as the Paule-Mandel estimator [21, 22]. Based
on an estimate of this heterogeneity τˆ , the mean effect
estimates are determined in a subsequent step by condi-
tioning on the τˆ value as if it were known.
The fully Bayesian estimation within the NNHM frame-
work is done using three different prior specifications for
the between-study heterogeneity (τ ). Uncertainty in the
heterogeneity is naturally accounted for when estimating
the combined treatment effect μ by marginalisation.
Especially if the number of studies is small, however,
Seide et al. BMCMedical ResearchMethodology           (2019) 19:16 Page 3 of 14
the choice of priors matters, as has been discussed by
Turner et al. [23], Dias et al. [24, Sec. 6.2], or Röver
[25]. We follow Friede et al. [3] and Spiegelhalter et al.
[26, Sec. 5.7] and consider two half-normal priors with
scales 0.5 and 1.0 for the between-study heterogene-
ity. These specifications include up to “fairly high” and
“fairly extreme” heterogeneity [26, Sec. 5.7.3], and they
also span the range of values considered in the simula-
tions (see Table 1). In all of these approaches risk ratios
(RR) and odds ratios (OR) can be used as the treatment
effect.
Generalized linear mixedmodels (GLMM)
Models
The statistical model may also be based directly on the
count data, using either a binomial or a Poisson assump-
tion on the numbers of events per study arm. Generalized
linear mixed models (GLMMs) may then be fitted to the
data, using a logarithmic link for Poisson rates or a logit
link for proportions. Treatment effects may be modeled
based onORs or RRs, and random effects may be included
at several stages in order to account for heterogeneity. In
addition, we also consider some approximate variants of
these models. The models used are outlined briefly below;
most of these are also discussed in more detail by Jackson
et al. [13].
Model specification and inference
If a Poisson distribution is assumed for the number of
events per arm and study, a log-link will be used to
model the RR. Following Böhning et al. [7, Ch. 2] this
model is estimated using the profile likelihood; in the
following, this model will be denoted as the “PN-PL”
model.
For binomially distributed numbers of events per study
arm, a logit-link will be applied to model ORs in a logis-
tic regression. Four different specifications are included
in the comparison. Unconditional logistic regression with
fixed and random study-specific nuisance parameters as
discussed by Turner et al. [27] are considered (“UM.FS”
and “UM.RS”, respectively, in the following). These corre-
spond to models 4 and 5 in Jackson et al. [13].
In addition, we follow van Houwelingen et al. [28] in
using a conditional logistic approach, where the total
number of events per study is conditioned upon, in order
to avoid the need to also model their variability [19].
The likelihood of this conditional model can be described
using Fisher’s non-central hypergeometric distribution
[28] (“CM.EL” in the following, and corresponding to
model 7 in [13]).
Fisher’s non-central hypergeometric distribution may
be approximated by a binomial distribution, if the number
of cases is small compared to the overall participants in
that study [29]; this model specification will be denoted by
“CM.AL” in the following (approximate version of model 7
in [13, Sec. 3.7.2]). All of the logistic regression models are
fitted using maximum likelihood.
Confidence and credible intervals combined effects
The 95% credible intervals in the Bayesian estimation
and confidence intervals in the frequentist approaches
are estimated for the combined treatment effect μ. The
narrowest 95% highest posterior density intervals are
used in the Bayesian estimation. For the construction of
confidence intervals, Wald-type intervals based on nor-
mal quantiles are considered, which are known to be
anti-conservative when the number of studies is small
or non-negligible amounts of heterogeneity are present
Table 1 Absolute heterogeneity values (τ ) corresponding to relative settings
(
I2
)
used in the simulations that are shown in Figs. 4 and 5
Relative risk (RR) Odds ratio (OR)
I2 Equal One small One large Equal One small One large
k=2 0.25 0.0534 0.1254 0.0396 0.1781 0.4179 0.1321
0.50 0.0926 0.2171 0.0687 0.3086 0.7237 0.2289
0.75 0.1604 0.3761 0.1189 0.5345 1.2536 0.3964
0.90 0.2777 0.6514 0.2060 0.9258 2.1712 0.6866
k=3 0.25 0.0534 0.1069 0.0447 0.1781 0.3563 0.1491
0.50 0.0926 0.1852 0.0775 0.3086 0.6172 0.2582
0.75 0.1604 0.3207 0.1342 0.5345 1.0690 0.4472
0.90 0.2777 0.5549 0.2324 0.9258 1.8516 0.7746
k=5 0.25 0.0534 0.0844 0.0484 0.1781 0.2981 0.1613
0.50 0.0926 0.1549 0.0838 0.3086 0.5164 0.2795
0.75 0.1604 0.2683 0.1452 0.5345 0.8944 0.4840
0.90 0.2777 0.4648 0.2515 0.9258 1.5491 0.8384
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[2, 3, 30, 31]. To account for this behaviour, confidence
intervals are in addition constructed using Student’s t-
distribution in case of the GLMMs, and the Hartung-
Knapp-Sidik-Jonkman (HKSJ) adjustment [30–32] in case
of the NNHM. The HKSJ-adjusted intervals tend to be
wider than the Wald-type intervals, although this is not
strictly the case [2, 32, 33]. Knapp and Hartung [33]
proposed a modification of the Hartung-Knapp-Sidik-
Jonkman adjustment (mHKSJ) correcting HKSJ-adjusted
intervals in the cases where they are counterintuitively
narrow. These modified confidence intervals are also
considered.
I2 as measure of between-study heterogeneity
The “relative amount of between-study heterogeneity” can
be expressed in terms of the measure I2, which expresses
the the between-study variance (τ 2) in relation to the
overall variance (σ˜ 2) [34], which is stated as
I2 = τˆ
2
σ˜ 2 + τˆ 2 . (2)
In the calculation of I2, a “typical” σ˜ 2 value is required
as an estimate of the within-study variances σ 2i . Higgins
and Thompson [34] suggest a weighted average of the
individual within-study variances as “typical” value. This,
together with the fact that the I2 is bounded between zero
and one, permits the interpretation of heterogeneity mag-
nitude as a relative percentage. The I2 is used to set the
amount of heterogeneity in the simulation study. Hoaglin
[35] remarks that the probability for observing a moder-
ate (estimated) I2 even in the absence of heterogeneity is
dependent on the number of studies included and is not
negligible. As the I2 expresses the between-study variation
relative to the total variation, the same values of τ may
lead to different values of I2, depending on the precision
of the underlying studies and should therefore always be
interpreted as a relative measure [36].
Extraction of the empirical data set
A data set of 40 meta-analyses was extracted from pub-
lications of the German Institute for Quality and Effi-
ciency in Health Care (IQWiG). IQWiG publications were
searched chronologically for meta-analyses of binary data
in April 2017 starting with the most recent available ones
and reaching back toMarch 2012. In total, 521 documents
were screened, including all document types in the search.
If a detailed and a short version of a document existed,
only the detailed version was considered. From docu-
ments including at least one meta-analysis of binary data,
the first one was extracted to obtain a realistic data set
with respect to the number of studies typically included
in a meta-analysis and the sample sizes of those studies.
Meta-analyses involving studies with zero events in one
or more arms were excluded from the data set for better
comparability of the evaluated methods.
Simulation procedure
To compare properties of the investigated approaches to
meta-analysis, we conducted a Monte-Carlo simulation
adapting the setup from IntHout et al. [14] who described
the simulation of 2×2 tables. In deviation from IntHout
et al. [14], series of trials with up to 10 studies were simu-
lated, and each series was repeated only 2000 times. Three
different designs were considered, where in the first one all
studies were of equal size, one study was ten times larger
than the other studies in the second, and one study was
only a tenth of the size of the other studies in the third
design. It should be noted however that this ratio cor-
responds to extreme, but not unrealistic cases, as is also
illustrated in the right panel of Fig. 1. The (less common)
case of equal sizes is of interest here, as this is where we
expect the HKSJ methods to perform best [2, 14].
To generate dichotomous outcomes, p0 and I2 have to
be set in advance. Considered values of the I2 correspond
to levels of no, low, moderate, high and very high het-
erogeneity, respectively [37]. Note however, that the same
I2 value may correspond to different values of between-
study heterogeneity τ depending on the effect measure
used, and on whether or not study sizes are balanced;
the resulting τ values are shown in Table 1. From the
τ values one can see that in some of the scenarios, the
I2 settings imply unrealistically large absolute heterogene-
ity [26, Sec. 5.7.3], which needs to be considered in the
interpretation. This would be true for instance for odds
ratios with I2 in the range of 0.75 and 0.90 and one
small study when τ is roughly in the range of 1 to 2 (see
Table 1). The baseline event rate (p0) needs to be set as
an additional parameter and varies from 0.1 to 0.9 in steps
of 0.2. The treatment effect θi is set to unity for both RR
and OR, which corresponds to the absence of an effect.
Note that while for meta-analyses of continuous (or, more
specifically, normally distributed) endpoints the magni-
tude of the simulated treatment effect (θi) should not
affect performance, e.g. for binomial counts it may make
a difference, as it affects the chances of observing few or
zero events in the treatment arm. However, since we chose
not to focus on rare-event issues, and in order to keep
the number of simulation scenarios manageable, only the
case of no effect was investigated. For every combination
of the simulation parameters 2000 repetitions are simu-
lated. In case zero event counts occurred, for the models
based on the NNHM, a continuity correction of 0.5 was
added to all cells of the affected study’s contingency table.
Zero counts, however, were rare in the scenarios consid-
ered. The simulation scenarios are also summarized in
Table 2. For more details on the simulation procedure see
also IntHout et al. [14] and Fig. 2 below. As in the case of
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Fig. 1 Characteristics of the data set extracted from IQWiG publications. Left side: Proportions of number of studies included per meta-analysis out
of n = 40. Colours indicate the effect measure used in the original publications. Right side: Empirical distribution function for the proportion of study
sizes (largest vs. smallest per meta-analysis, black) and the proportion of study-specific variances (largest vs. smallest per meta-analysis) for the
log-transformed RR (green) and the log-transformed OR (orange). All meta-analyses are included for both effect measures
the empirical data set, the two-sided significance level α
was set to 0.05. Different methods and scenarios are com-
pared based on observed confidence or credible interval
coverage probabilities and lengths.
Estimation in R
The software environment R [38] and two of its exten-
sions, the metafor [39, 40] and bayesmeta [25, 41]
packages are used with their default options. As no
implementation in R was found for the PL estimation of
Poisson-normal model we translated the steps described
by Böhning et al. [7, Ch. 2] into R code which is shown in
the Additional file 1.
Results
Empirical study
Most (419; 80%) of the 521 documents searched did not
include a meta-analysis, because either the assignment
was canceled (11; 2%), the assignment had just started
without results being available at the time of search (70;
13%), no meta-analysis was included or accepted by the
IQWiG (186; 36%), no study (34; 7%) or just one study
(118; 23%) was identified. Out of the remaining 102 docu-
ments which included at least one meta-analysis, 25 (5%)
did not include any binary meta-analysis, 19 (4%) were
network meta-analyses, and in 18 (3%) cases the first
binary meta-analysis included at least one study with zero
events. An overview over the identified meta-analyses is
given in Table 3; the data are also available online [42].
In the original publications, a slight majority of studies
(26 of 40) was analyzed using RR as the effect measure.
In the extracted data set, 21 out of the 40 meta-analyses
(53%) included only 2 studies, while 10 (25%) consisted
of three studies. Even in this small example, a common
Table 2 Parameters of the simulation for both effect measures,
i.e., relative risk and odds ratio
Parameter Values
Effect measure (θi) RR, OR
Design Equally sized studies,
One small study ( 110 size)
One large study (10-fold size)
Observations per study arm (ni) 25, 50, 100, 250, 500, 1000
Number of studies (k) 2, 3, 5, 10
Event rates (p0) 0.1, 0.3, 0.5, 0.7, 0.9
Level of heterogeneity
(
I2
)
No heterogeneity: 0.00
Low heterogeneity: 0.25
Moderate heterogeneity: 0.50
High heterogeneity: 0.75
Very high heterogeneity: 0.90
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Fig. 2 Generation of data sets in the simulation study
occurrence of 2- and 3-study meta-analyses is found,
which is also observed empirically by [43] and [44]. The
distribution of study sizes and endpoints is also illustrated
on the left panel in Fig. 1. With only two studies included,
three methods coincide: the DL, the REML and the EB
estimation [45]. As this is the case for a major share of the
data set, these three methods are expected to show similar
results in the analysis. The maximum number of studies
observed is 18. The original analyses were based on the
NNHM, and, with only the exceptions of the publications
A15-45, S11-01 and A11-30 performed using DL variance
estimation.
Imbalance in study sizes may influence the estimation
of an overall treatment effect [2, 14, 46]. As IntHout
et al. [14] observe in an empirical study, such unequal
study sizes are common in meta-analyses. In the data set
extracted from IQWiG publications, ratios of sample sizes
between the largest and the smallest study in a meta-
analysis ranged from 1.0 up to 15.8, with a mean of 3.4 and
a median of 1.9. Nearly half of the meta-analyses included
at least one study twice as large as the smallest study. In
the NNHM, study-specific variances σ 2i should roughly
be inversely proportional to sample sizes; imbalances in
sample size then affect analysis via an imbalance in the σi.
Ratios of largest to smallest study sizes and variances using
both effect measures for all studies are shown on the right
panel in Fig. 1, where the ratio between the largest and
the smallest value is ordered by the ratio of sample sizes
in descending order. It can be observed that the ratios of
the variances of ORs seem to vary more when study sizes
are unbalanced than those of the RRs. However, they both
roughly follow the same pattern as the ratio of study sizes.
The extracted data set is then analyzed based on the
models and methods described above. As 2×2 tables are
available for all studies, both effect measures are used
to summarize the individual meta-analyses and to eval-
uate the influence of the choice of effect measure on
the estimation results. The ratios of point estimates of
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Table 3 Data extracted from IQWiG publications [42]
No. Identifier Date Endpoint Page Number of studies (k) Effect measure
1 N15-06 2017-03 Morning pain 85 5 OR
2 N15-11 2017-03 Ear infection 62 2 OR
3 S15-02 2017-01 Mortality 53 2 OR
4 D15-02 2017-01 Mortality 74 2 OR
5 A16-71 2016-12 Morbidity 5 6 OR
6 A16-38 2016-12 Vomiting 4 2 RR
7 P14-03 2016-11 Breast cancer screening 55 3 RR
8 N14-02 2016-08 Remission from anxiety disorder 127 2 OR
9 A16-30 2016-08 AIDS-defining events 103 2 RR
10 N15-07 2016-08 Ejaculation dysfunction 89 4 OR
11 A16-11 2016-06 Serious adverse events 86 2 RR
12 A10-03 2016-04 Serious adverse events 89 2 OR
13 A15-57 2016-02 St. George’s respiratory questionnaire response 22 2 RR
14 A15-45 2016-01 Morbidity 24 2 OR
15 A15-31 2015-11 Mortality 87 2 RR
16 A15-25 2015-10 Serious adverse events 89 2 RR
17 A15-21 2015-07 Mortality 16 2 RR
18 S13-04 2015-05 Screening for abdominal aortic aneurysm 71 4 OR
19 A15-06 2015-05 Morbidity 96 3 RR
20 A15-05 2015-03 Morbidity 4 2 RR
21 A14-38 2015-01 Serious adverse events 65 3 RR
22 A14-25 2014-11 Serious adverse events 115 2 RR
23 A14-22 2014-10 Transition Dyspnea Index responder 67 2 RR
24 A14-19 2014-09 Urge to urinate 75 3 RR
25 A14-18 2014-09 Persistent virological response (SVR24) 194 3 RR
26 S13-03 2014-06 Participants with cervical intraepithelial neoplasia 3+ 15 6 RR
27 A13-29 2013-10 Metformidosis 15 3 RR
28 A10-01 2013-08 Remissions 1183 2 OR
29 A13-20 2013-08 Visual acuity 28 3 RR
30 S11-01 2013-07 Bowel cancer 61 7 OR
31 A13-23 2013-06 Mortality 15 2 RR
32 A13-05 2013-04 Full recovery 19 4 RR
33 A05-10 2013-04 Cardiovascular death 75 3 RR
34 A12-19 2013-03 Ocular adverse event 17 2 RR
35 A05-18 2012-08 Serious adverse events 67 18 OR
36 A12-10 2012-07 Adverse events 20 3 RR
37 A12-03 2012-04 Loss of transplant 23 2 RR
38 A12-04 2012-04 Virus occurrence 22 3 RR
39 A09-05 2012-04 Alzheimer’s disease assessment scale 51 6 OR
40 A11-30 2012-03 Mortality 24 2 OR
the different methods against the standard DL approach
are illustrated by the first row of Fig. 3 where the RR is
displayed in the left and the OR in the right panel. As
expected, DL, REML and EB estimation coincide in the
majority of cases including only two studies [45]. These
three estimators are also observed to behave compara-
ble when more than two studies are included, as do the
point estimates of the Bayesian approach. The greatest
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Fig. 3 Estimates of the combined treatment effect and lengths of confidence or credible intervals for both effect measures, empirical data set. The
first row shows the treatment effect estimates for the RR (left column) and the OR (right column) compared to the standard DL approach. Colours
indicate the various methods. The second row illustrates the length of confidence or credible intervals and the respective adjustments, again for the
RR (left column) and the OR (right column)
deviation from the standard DL approach is observed
in the GLMMs in both effect measures. In the case
of OR as an effect measure, UM.FS and UM.RS per-
form comparable. CM.EL estimation does not converge
in all cases, however, in the cases where convergence was
achieved, it is in line with DL estimation. The CM.AL
however, is in general different from the DL estimation.
The Poisson-based results also differ considerably from
the DL estimates.
The length of confidence intervals for the frequentist
and credible intervals in the Bayesian estimation are also
of importance as it might not be possible to detect signifi-
cant treatment effects if intervals are inconclusively wide.
For both effect measures, all intervals and the discussed
adjustments are shown in the second row in Fig. 3. Again,
the RR is displayed in the left and theOR in the right panel.
The Bayesian credible intervals are generally wider than
the unadjusted confidence intervals and more similar to
the adjusted ones with respect to the median length, but
exhibiting less variability.
Simulation study
Figures 4 and 5 illustrate the coverage rates (first row)
and lengths (second row) of the 95% confidence or credi-
ble intervals of the different methods for the relative risks
and odds ratios, respectively. All results shown here exem-
plarily refer to the combination of 100 participants per
arm and study and a baseline event rate of 0.7. Results
of the other scenarios may be found in the supplement
(see Additional files 2 and 3). The different methods are
indicated by colours, while the different adjustments are
indicated by the line type.
Non-convergence rates averaged over all scenarios
and both effect measures are mostly negligible in the
methods based on the normal likelihood on the log-
scale (ML: 0.049%, EB: 0.032%, HN(1.0): 0.002%, HN(0.5):
0.036%). Estimation based on REML or the methods tak-
ing the distributional assumptions on the trial-arms lead
to slightly higher non-convergence rates (REML: 0.43%,
UM.FS: 0.43%, UM.RS: 0.22%, CM.AL: 0.47%). The only
method with high non-convergence rates is CM.EL, with
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an average of 18%. None of the methods fully dominates
the others over the range of the investigated scenarios.
Estimation using CM.EL for the binomial-normal model
however was computationally expensive and convergence
was problematic in a large proportion of scenarios (using
the default values), as has been noted before [13, 19]; these
results are omitted here. Coverage rates of all methods are
comparable when either the number of studies included
in each meta-analysis is sufficiently large or when the het-
erogeneity is absent or low
(
I2≤0.25). However, given the
frequency with which 2- or 3-study meta-analyses occur
empirically in our example data set and others [43, 44]
Fig. 4 Coverage probabilities and lengths of 95% confidence or credible intervals for the overall effect for RR effects based on the simulated data.
The top panel shows the coverage probabilities of treatment effect CIs for the different methods (colours) and adjustments (line types). The grey
area indicates the range expected with 95% probability if the coverage is accurate. The bottom panel similarly shows the lengths of 95% confidence
or credible intervals. Results are illustrated for a study size of ni =100 and a baseline event probability p0=0.7, and are based on 2000 replications
per scenario. CM.EL is omitted due to low convergence rates
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Fig. 5 Coverage probabilities and lengths of 95% confidence or credible intervals for the overall effect for OR effects based on the simulated data.
The top panel shows the coverage probabilities of treatment effect CIs for the different methods (colours) and adjustments (line types). The grey
area indicates the range expected with 95% probability if the coverage is accurate. The bottom panel similarly shows the lengths of 95% confidence
or credible intervals. Results are illustrated for a study size of ni =100 and a baseline event probability p0=0.7, and are based on 2000 replications
per scenario. CM.EL is omitted due to low convergence rates
and the difficulties in the determination of the absence of
heterogeneity [2] this is hardly relevant in practice. In gen-
eral when study sizes were not balanced, coverage rates for
all methods were substantially lower even in the presence
of only low heterogeneity in the simulation of OR, while
Bayesian estimation and the adjustment of frequentist
confidence intervals resulted in better coverage when RR
was used. This might be due to the I2 values translating to
lower values of absolute heterogeneity in the latter case.
In the presence of heterogeneity, coverage could drop as
low as 40% for some extreme scenarios in both, frequentist
and Bayesian estimation, resulting in high false-positive
Seide et al. BMCMedical ResearchMethodology           (2019) 19:16 Page 11 of 14
rates. In general, it was also observed that one large study
tended to lead to lower coverage than one small study
per meta-analysis in the frequentist methods when more
than k = 2 studies are present, which is in line with [14].
This effect is more noticeable in the unadjusted meth-
ods, in scenarios where the number of patients per arm
(ni) is small, or when heterogeneity
(
I2
)
is large. When
considering k = 2 trials per meta-analysis, coverages are
comparable (OR) or the effect is even reversed (RR). The
frequentist methods based on the normal-normal hier-
archical model perform similarly, or, in the case of two
studies per meta-analysis, even identically [45]. In the case
of heterogeneous data, in particular regarding small study
sizes, all frequentist methods perform below the nomi-
nal coverage probability when confidence intervals are not
adjusted. In the scenarios with unbalanced study sizes this
is even more pronounced than in the balanced scenarios;
this is in line with the findings of [14] and [2]. Coverage
can, at the cost of interval width, be increased by either
using the HKSJ or the mHKSJ adjustment, but the HKSJ
adjustment yields in some scenarios coverage probabilities
which are still below the nominal level [14].
The length of confidence and credible intervals is illus-
trated in the second row of Figs. 4 and 5. Bayesian credible
intervals are, as in the case for the empirical data set,
in general wider than the unadjusted confidence inter-
vals from the frequentist estimations. When compared
to adjusted confidence intervals, Bayesian credible inter-
vals tend to be, especially in the presence of heterogeneity
and with only two studies per meta-analysis, narrower
than the frequentist intervals based on the normal-normal
model as long as the number of patients per trial arm is
small. However, when ni increases, this is no longer true
for RR (in contrast to the scenarios using OR). These dif-
ferences may be due to the fact that idential I2 settings
can imply very different (and sometimes possibly unreal-
istically large) magnitudes of heterogeneity values on the
τ scale, as can also be seen in Table 1. In these extreme
scenarios, adjusted frequentist confidence intervals are
observed to be inconclusively wide, with the exception
of BN-UM.FS and BN-UM.RS, and especially when esti-
mation is based on the NNHM. In the other scenarios,
Bayesian credible and adjusted confidence intervals are
comparable.
Discussion
In our empirical study we found that the majority of
the 40 meta-analyses extracted from publications of
IQWiG included only two studies. This is in agreement
with a much larger empirical investigation based on the
Cochrane Library by Turner et al. [1]. This finding empha-
sizes the need for methods appropriate for meta-analysis
with few studies. Furthermore, varying methods and /
or effect measures lead to differences in the results for
the 40 meta-analyses considered. This demonstrates that
prespecification of methods as well as effect measures is
important for controlling operating characteristics. The
problems encountered in meta-analyses of few studies
may mostly be attributed to the estimation of hetero-
geneity, and in particular to the proper accounting for
its uncertainty in constructing intervals for the combined
effect. The difference in performance between different
heterogeneity estimators is relatively small compared to
the difference in whether or how heterogeneity uncer-
tainty is propagated through to the effect estimate [3].
In the simulation study, coverage probability was below
the nominal level for all frequentist methods in the pres-
ence of heterogeneity and few studies. This phenomenon
is even more pronounced when studies included in a
meta-analysis are of unequal size. However, coverage
probabilities generally improve when confidence intervals
are adjusted based on the Student-t-distribution. Bayesian
methods mostly result in better coverage across all sce-
narios, except for some cases of very large heterogeneity
(in terms of τ ) where the coverage is slightly lower. Cred-
ible intervals are empirically and in the simulation study
wider than unadjusted confidence intervals, but consider-
ably narrower than adjusted ones, with some exceptions
when considering RRs and large numbers of patients
per trial-arm. Previous simulation studies comparing a
more restricted set of methods including standard fre-
quentist and Bayesian approaches only led to similar
conclusions. The simulations presented here consider-
ing a wider set of methods show that the issues entailed
by the increased complexity of some likelihood-based
approaches may often outweigh their expected advan-
tages [6]. However, confidence intervals based on the
GLMMs for example are in general slightly narrower than
those from other frequentist methods. Furthermore, cer-
tain maximum-likelihood methods turned out to suffer
from frequent numerical problems in the setting with few
studies. To our knowledge, this has not been described
previously.
Our empirical investigation did not consider all IQWiG
reports, but only the most recent 40 meta-analyses at the
time of extraction. A consideration of all meta-analyses
might have led to a more complete picture, but was not
feasible with the resources of this project as no spe-
cific funding was available. Furthermore, the simulation
study could have been enriched by additional meth-
ods. For instance, we only considered Bayesian two-stage
approaches but did not include Bayesian approaches uti-
lizing the full information of the 2×2 tables. The latter
was considered recently by [47] in the context of network
meta-analyses, where pairwise meta-analysis would be a
special case. As for the likelihood methods, we would
expect that the results of the one-stage approach are
overall quite similar to those of the two-stage approach
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Table 4 Abbreviations used for analysis models
NN-DL Normal-normal (NN) model using the DerSimonian-Laird (DL) heterogeneinty estimator
NN-REML NN model using the restricted maximum-likelihood (REML) estimator
NN-EB NN model using the empirical-Bayes (EB) estimator
PN-PL Poisson model using profile likelihood (PL) estimation
BN-UM.FS Binomial model using unconditional logistic regression and fixed study (nuisance) parameters
BN-UM.RS Binomial model using unconditional logistic regression and random study (nuisance) parameters
BN-CM.EL Conditional (hypergeometric) model (exact likelihood)
BN-CM.AL Conditional (hypergeometric) model (approximate likelihood)
NN-Bayes HN(0.5) NN Bayesian model using a half-normal heterogeneity prior with scale 0.5
NN-Bayes HN(1.0) NN Bayesian model using a half-normal heterogeneity prior with scale 1.0
considered, maybe with the potential of some small
improvements. As discussed in the context of the simu-
lation setup, a pre-specified I2 value may correspond to
rather different τ values, depending on the circumstances
(see also Table 1). Consequently, one may generally expect
larger I2 values for log-RR endpoints, and smaller I2 val-
ues for log-OR endpoints, while heterogeneity priors are
probably best discussed at the scale of τ values (a prior
specification in terms of I2 would be possible [25], but
this would be hard to motivate). By relating the hetero-
geneity to the τ value, the question to consider is by what
factor the true RRs or ORs θi are expected to differ solely
due to between-trial heterogeneity [26, Sec. 5.7.3], and
the reasonably expected range should then be covered by
the prior. For example, a heterogeneity of τ = 1.0 implies
that the central 95% of true study means (θi) span a range
of a factor of 50 [3, 26]. The HN(0.5)-prior confines τ
to values below 1.0 with roughly 95% probability, while
theHN(1.0)-prior constitutes a conservative variation that
instead allows for twice as large heterogeneity, implying a
plausible range of roughly up to factor of 502 = 2500.
The limits of applicability of approximate meta-analysis
methods have been discussed from the perspective of the
NNHM by Jackson and White [48]. In the limit of many
studies (large k) and large sample sizes (large ni), the
normal approximation usually works well. It starts break-
ing down, however, when the number of studies (k) gets
too small. The problem then is related to the estima-
tion of heterogeneity (τ ) and proper accounting for the
associated uncertainty; inference would still be exact if
the heterogeneity was known. In the frequentist context,
use of the HKSJ adjustment helps, especially if the study-
specific standard errors are roughly balanced [49]. This is
not so much of a problem when Bayesian methods along
with reasonable priors are used; these methods yield valid
inference irrespective of the number of included studies
[50]. Problems also arise when events are rare or sample
sizes (ni) are small. In either case, the chances of observ-
ing few or no events in a treatment group increase, and
normal approximations to the likelihood break down. In
such situations, a solution might be to resort to exact
likelihoods respecting the discrete nature of the data, for
example a GLMM,whichmay again be done in frequentist
or Bayesian frameworks [7, 40, 51].
Conclusions
In the presence of between-study heterogeneity, especially
with unbalanced study sizes, caution is needed in applying
meta-analytical methods to few studies, as either cover-
age probabilities of intervals may be compromised, or they
may be inconclusively wide. Bayesian estimation with sen-
sibly chosen prior for the between-study heterogeneity
may offer a compromise and promising alternative.
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